Pfizer (PFE) Debt Ratio (2009 - 2026)

Pfizer (PFE) has reported Debt Ratio for 18 consecutive years, with 0.31 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Debt Ratio rose 4.78% year-over-year to 0.31 in Q2 2026; TTM through Jun 2026 was 0.31, a 4.78% increase from a year earlier, with the FY2025 full-year figure at 0.31, up 3.22% from the prior year.
• Debt Ratio was 0.31 for Q2 2026 at Pfizer, up from 0.31 in the prior quarter.
• Over five years, Debt Ratio peaked at 0.32 in Q2 2024 and troughed at 0.18 in Q4 2022.
• A 5-year average of 0.28 and a median of 0.3 in 2025 frame the typical range for Debt Ratio.
• Across the five-year window, Debt Ratio decreased 21.07% in 2022 and surged 74.86% in 2023, its largest moves.
• Over 5 years, Debt Ratio stood at 0.18 in 2022, then surged by 74.86% to 0.32 in 2023, then dropped by 5.39% to 0.3 in 2024, then grew by 3.22% to 0.31 in 2025, then climbed by 0.94% to 0.31 in 2026.
• The last three Debt Ratio figures came in at 0.31 (Q2 2026), 0.31 (Q1 2026), and 0.31 (Q4 2025), per Business Quant data.